الفهرس 
ANATOMY OF OVARIESOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
O
varian cancer is the second most common gynecologic malignancy (after cervical cancer), with a lifetime risk of 1.7%. Up to 75% of the treated patients with advanced disease present with recurrence within two years.
CT and MRI are the most commonly used imaging modalities in patients with suspected recurrent ovarian cancer. PET scan opened a new field in clinical oncologic imaging. Originally, PET lacks anatomic information. Integrated PET/CT acquires both metabolic and anatomic imaging data using a single device and provides precise anatomic localization of suspicious areas of increased FDG uptake.
Our study included 25 patients who have been diagnosed with ovarian cancer, received treatment and achieved complete response. All of the 25 patients had suspected recurrence either due to elevated tumor markers or suspicious clinical findings. The 25 patients have been referred for PET/CT scan at ELDemerdash university hospital from July 2017 to August 2018.
All patients underwent CECT scan as a part of the PET/CT scan. CECT images were interpreted first, then the fused PET/CT images. Some patients were proved to have recurrent disease by histopathology and the rest of the patients were followed up for a time period of 3 to 6 months. 19 patients out of the 25 patients were diagnosed with recurrent ovarian cancer.
In our study PET/CT had a higher sensitivity, specificity and accuracy than CECT alone and also higher than CA125 in detection of recurrent ovarian cancer.